Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Liabilities and Shareholders Equity (2022 - 2025)

Taysha Gene Therapies' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $316.6 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 75.65% year-over-year to $316.6 million; the TTM value through Sep 2025 reached $948.6 million, up 34.3%, while the annual FY2024 figure was $160.4 million, 7.16% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $316.6 million at Taysha Gene Therapies, down from $333.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $333.3 million in Q2 2025 and bottomed at $81.5 million in Q2 2023.
  • The 4-year median for Liabilities and Shareholders Equity is $160.4 million (2024), against an average of $172.0 million.
  • The largest annual shift saw Liabilities and Shareholders Equity tumbled 42.71% in 2023 before it skyrocketed 145.75% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $126.3 million in 2022, then soared by 36.79% to $172.7 million in 2023, then dropped by 7.16% to $160.4 million in 2024, then soared by 97.4% to $316.6 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Liabilities and Shareholders Equity are $316.6 million (Q3 2025), $333.3 million (Q2 2025), and $138.4 million (Q1 2025).